

# Disease-modifying Treatment in High-risk CIS

Agent	Study Name	Entry Criteria	Results
IM IFN $\beta$ -1a 30 mcg weekly (Avonex)	CHAMPS/CHAMPIONS ( <i>NEJM</i> . 2000;343:898-904; <i>Neurology</i> . 2006;66:678-684)	2 or more MRI lesions	Lower rate of MS dx at 3 years (35% vs. 50%)
SC IFN $\beta$ -1a 22 mcg weekly (low-dose Rebif)	ETOMS ( <i>Lancet</i> . 2001;357:1576-1582)	4 or more MRI lesions or 3 lesions if one enhancing or infratentorial	Lower rate of MS dx at 2 years (34% vs. 45%)
SC IFN $\beta$ -1a 44 mcg TIW (Rebif)	REFLEX ( <i>Lancet</i> . 2012;11:33-41)	2 or more MRI lesions	Lower rate of MS dx at 2 years (21% vs. 38%)
SC IFN $\beta$ -1b 250 mcg qod (Betaseron)	BENEFIT ( <i>Neurology</i> . 2006;67:1242-1249; <i>Lancet</i> . 2007;370:389-397)	2 or more MRI lesions	Lower rate of MS dx at 2 years (28% vs. 45%); decreased disability development
Glatiramer acetate 20 mg SC daily (Copaxone)	PreCISe ( <i>Lancet</i> . 2009;374:1503-1511)	2 or more lesions	Lower rate of MS diagnosis (45% reduction at 36 months)